| Ytd | -16.73% | |
| 1y | -30.40% |
| Open | 1.90 | Prev Close | 1.91 | Low | 1.86 | High | 1.91 | Mkt Cap | 744.48M |
| Vol | 63.92K | Avg Vol | 1.43M | EPS | -0.55 | P/E | N/A | Forward P/E | -5.33 |
| Beta | 1.70 | Short Ratio | 3.72 | Inst. Own | 30.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 1.66 | 200-d Avg | 1.93 | 1yr Est | 5.83 |
PROK News
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst cons
Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy an
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consens
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst cons
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) wi
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consen
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney
As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor w
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consen
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-
UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilpar
Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price
Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the p
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a mark
U.S. stock futures advanced on Wednesday after ending on a mixed note on Tuesday. Futures of major b
Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the co
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained
U.S. major indices ended mixed on Tuesday, as the Dow Jones Industrial Average slipped nearly 0.4% t
ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function dec
NDRA: 156% | ENDRA Life Sciences shares are trading higher after the company announced it will be gr
B of A Securities analyst Jason Gerberry downgrades ProKidney (NASDAQ:PROK) from Neutral to Under
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consen
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.62) per share which missed the analyst cons
